Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma, A Phase I Study

NCT00509353 is registered in ClinicalTrials.gov with New Approaches to Neuroblastoma Therapy Consortium as lead sponsor.

NCT NCT00509353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00509353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma, A Phase I Study
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2007
Completion date
May 31, 2012
Enrollment
26 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma